Skip to main content

7 Result(s)

within English Remove this filter Medicine & Public Health Remove this filter Oncology Remove this filter Brian M Wolpin Remove this filter Article Remove this filter

and

  1. No Access

    Article

    A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

    Background MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 i...

    Jason E. Faris, Jamie Arnott, Hui Zheng, David P. Ryan… in Investigational New Drugs (2012)

  2. No Access

    Article

    Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

    Purpose Resistance to cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), in colorectal cancer (CRC) may result from compensatory signaling through ErbB...

    Douglas A. Rubinson, Howard S. Hochster, David P. Ryan… in Investigational New Drugs (2014)

  3. No Access

    Article

    A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

    Background Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an ...

    Lipika Goyal, Raymond C. Wadlow, Lawrence S. Blaszkowsky… in Investigational New Drugs (2015)

  4. Article

    Open Access

    Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

    Background In pancreatic ductal adenocarcinoma (PDAC), the chemokine (C-C motif) ligand 2 (CCL2)/chemokine (C-C motif) receptor 2 (CCR2) axis plays a key role in immunosuppressive properties of the tumor microenv...

    Marcus Noel, Eileen M. O’Reilly, Brian M. Wolpin… in Investigational New Drugs (2020)

    Download PDF (526 KB) View Article

  5. No Access

    Article

    A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

    Subsets of esophagogastric (EG) cancers harbor genetic abnormalities, including amplification of HER2, MET, or FGFR2 or mutations in PIK3CA, EGFR, or BRAF. Ganetespib which is a novel triazolone heterocyclic i...

    Lipika Goyal, Surendra Pal Chaudhary, Eunice L. Kwak… in Investigational New Drugs (2020)

  6. Article

    Open Access

    Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

    The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and strategies to overcome resistance are poo...

    James M. Cleary, Betty Rouaisnel, Antoine Daina… in npj Precision Oncology (2022)

    Download PDF (2169 KB) View Article

  7. No Access

    Article

    A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer

    AbGn-107 is an antibody–drug conjugate directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in a variety of gastrointestinal (GI) malignancies. Based on promising antitumor activity of AbGn-1...

    Andrew H. Ko, Andrew L. Coveler, Benjamin L. Schlechter… in Investigational New Drugs (2024)